J. Palma

发表

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Anticancer research.

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Eric F. Johnson, X. Liu, V. Giranda, 2008, Molecular Cancer Research.

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

P. Ellis, X. Liu, V. Giranda, 2009, Clinical Cancer Research.

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.

P. Ellis, X. Liu, V. Giranda, 2008, Analytical biochemistry.

The RTK inhibitor, ABT-869 alone or in combination with various cytotoxic therapies demonstrate significant tumor growth inhibition in orthotopic hepatocellular carcinoma, renal cell carcinoma and prostate xenografts

S. Davidsen, J. O'Connor, Baole Wang, 2007 .

AntitumorActivity of Orally Bioavailable Farnesyltransferase Inhibitor , ABT-100 , Is Mediated byAntiproliferative , Proapoptotic , and Antiangiogenic Effects in XenograftModels

S. Rosenberg, H. Sham, J. O'Connor, 2005 .

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

Haiying Zhang, N. Lin, H. Sham, 2005, Clinical Cancer Research.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

M. Maitland, M. Ratain, R. Kurzrock, 2018, British Journal of Cancer.

The scope and activation mechanisms of chemokine gene expression in primary astrocytes following infection with Theiler's virus

Byung S. Kim, J. Palma, 2004, Journal of Neuroimmunology.

Infection with Theiler's Murine Encephalomyelitis Virus Directly Induces Proinflammatory Cytokines in Primary Astrocytes via NF-κB Activation: Potential Role for the Initiation of Demyelinating Disease

N. Clipstone, Byung S. Kim, J. Palma, 2003, Journal of Virology.

Preferential Induction of IL-10 in APC Correlates with a Switch from Th1 to Th2 Response Following Infection with a Low Pathogenic Variant of Theiler’s Virus1

R. Yauch, Hee-Kap Kang, Byung S. Kim, 2002, The Journal of Immunology.

Role of Individual T-Cell Epitopes of Theiler’s Virus in the Pathogenesis of Demyelination Correlates with the Ability To Induce a Th1 Response

R. Yauch, C. Koh, Byung S. Kim, 1998, Journal of Virology.

Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.

K. Glaser, C. Tse, M. Michaelides, 2012, Bioorganic & medicinal chemistry letters.

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization

K. Glaser, S. Fesik, Mark G. Anderson, 2010, Proceedings of the National Academy of Sciences.

Potential role of CD4+ T cell-mediated apoptosis of activated astrocytes in Theiler's virus-induced demyelination.

R. Yauch, S. Lang, J. Palma, 1999, Journal of immunology.

Virus-Induced Demyelination Theiler ' sApoptosis of Activated Astrocytes in T Cell-Mediated + Potential Role of CD 4

R. Yauch, S. Lang, J. Palma, 1999 .

Induction of chemokines in human astrocytes by picornavirus infection requires activation of both AP‐1 and NF‐κB

I. Choi, J. Palma, D. Kwon, 2003, Glia.

Induction of selected chemokines in glial cells infected with Theiler's virus

Byung S. Kim, J. Palma, 2001, Journal of Neuroimmunology.

Preclinical Chemosensitization by PARP Inhibitors

D. Shalinsky, C. Donawho, G. Los, 2015 .

Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

K. Glaser, O. Shah, P. Tapang, 2009, The Pharmacogenomics Journal.

CD8-deficient SJL mice display enhanced susceptibility to Theiler’s virus infection and increased demyelinating pathology

S. Miller, M. D. Dal Canto, L. Haynes, 2001, Journal of NeuroVirology.

Enhanced susceptibility to Theiler's virus-induced demyelinating disease in perforin-deficient mice

S. Miller, M. Mohindru, B. Kang, 2001, Journal of Neuroimmunology.

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Eric F. Johnson, X. Liu, V. Giranda, 2009, Molecular Cancer Research.

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

Effects of the major histocompatibility complex loci and T‐cell receptor beta‐chain repertoire on Theiler's virus‐induced demyelinating disease

M. Mohindru, B. Kang, J. Palma, 2005, Journal of neuroscience research.

This information is current as Pathogenic Variant of Theiler's Virus Response Following Infection with a Low Correlates with a Switch from Th1 to Th2 Preferential Induction of IL-10 in APC

R. Yauch, Hee-Kap Kang, Byung S. Kim, 2013 .

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Restrições mercadológicas, produtivas e institucionais que afetam o desempenho de agroindústrias processadoras de lácteos orgânicos Marketing, production and institutional restrictions affecting the performance or organic dairy agroindustries

Aline Biedrzycki, Jean Philippe Palma, Luisa Wolker, 2012 .

Principles of Chemotherapy and Pharmacology

A. Shoemaker, C. Donawho, J. Palma, 2007 .

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody

A. Scott, A. Phillips, E. DiGiammarino, 2015, Molecular Cancer Therapeutics.

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

Kedar S Vaidya, L. Naumovski, Mark G. Anderson, 2016, Clinical Cancer Research.

Innate immune response induced by Theiler's murine encephalomyelitis virus infection

J. Palma, D. Kwon, B. S. Kim, 2005, Immunologic research.

Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

Kedar S Vaidya, A. Scott, Mark G. Anderson, 2020, Molecular Cancer Therapeutics.

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.

K. Gish, T. Uziel, D. Chao, 2018, Cancer research.

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

John E. Harlan, Ramesh Iyer, Yan Shi, 2011, Clinical Cancer Research.

Pharmacodynamic Evaluation of Irinotecan Therapy by FDG and FLT PET/CT Imaging in a Colorectal Cancer Xenograft Model

M. Day, P. Tapang, G. Fox, 2012, Molecular Imaging and Biology.

A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor

Kedar S Vaidya, Mark G. Anderson, W. N. Pappano, 2017, Pharmacology.

Pathogenic immunity in Theiler's virus-induced demyelinating disease: a viral model for multiple sclerosis.

C. Koh, A. Inoue, J. Palma, 2000, Archivum immunologiae et therapiae experimentalis.

Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR

Kedar S Vaidya, A. Phillips, P. Ansell, 2021, Journal of Neuro-Oncology.

Cancer Therapy : Preclinical Iniparib Nonselectively Modi fi es Cysteine-Containing Proteins in TumorCells and IsNot a Bona Fide PARP Inhibitor

P. Ellis, Eric F. Johnson, N. Soni, 2012 .

Antibody response is required for protection from Theiler's virus-induced encephalitis in C57BL/6 mice in the absence of CD8+ T cells.

M. D. Dal Canto, Byung S. Kim, J. Palma, 2005, Virology.

Pathogenesis of virus-induced immune-mediated demyelination

M. Mohindru, Hee-Gu Lee, J. Palma, 2001, Immunologic research.

Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity

L. Rubinstein, J. Doroshow, X. Liu, 2006 .

Cisplatin and carboplatin-mediated activation of murine peritoneal macrophages in vitro: production of interleukin-1 alpha and tumor necrosis factor-alpha.

J. Palma, S. Aggarwal, 1995, Anti-cancer drugs.

Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages in vitro

J. Palma, S. Aggarwal, 1994, Anti-cancer drugs.

Murine macrophage activation after cisplatin or carboplatin treatment

J. Palma, A. Jiwa, S. Aggarwal, 1992, Anti-cancer drugs.

Treatment with lipopolysaccharide enhances the pathogenicity of a low‐pathogenic variant of Theiler's murine encephalomyelitis virus

J. Palma, B. Kim, S. Park, 1996, Journal of neuroscience research.

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.

K. Gish, T. Uziel, D. Chao, 2018, Cancer research.